OLUX E's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7029659 | MYLAN | Mousse composition |
Sep, 2019
(4 years ago) | |
| US6730288 | MYLAN | Mousse composition |
Sep, 2019
(4 years ago) | |
| US8962000 | MYLAN | Microemulsion and sub-micron emulsion process and compositions |
Aug, 2025
(1 year, 4 months from now) | |
| US8460641 | MYLAN | Microemulsion process and composition |
Nov, 2028
(4 years from now) | |
Olux E is owned by Mylan.
Olux E contains Clobetasol Propionate.
Olux E has a total of 4 drug patents out of which 2 drug patents have expired.
Expired drug patents of Olux E are:
- US7029659
- US6730288
Olux E was authorised for market use on 12 January, 2007.
Olux E is available in aerosol, foam;topical dosage forms.
Olux E can be used as treatment of corticosteroid-responsive dermatoses.
The generics of Olux E are possible to be released after 05 November, 2028.
Drugs and Companies using CLOBETASOL PROPIONATE ingredient
Market Authorisation Date: 12 January, 2007
Treatment: Treatment of corticosteroid-responsive dermatoses
Dosage: AEROSOL, FOAM;TOPICAL
How can I launch a generic of OLUX E before it's drug patent expiration?
More Information on Dosage
OLUX E family patents
